Table 3 Adverse Events
Parameter | Boceprevir-experienced | Telaprevir-experienced | ||
|---|---|---|---|---|
LDV/SOF (n = 63) | PrOD (n = 64) | LDV/SOF (n = 105) | PrOD (n = 103) | |
Patients with at least one AE, n (%) | 24 (38.1%) | 28 (43,8%) | 44 (41.9%) | 45 (43.7%) |
RBV-containing regimen | 18 (28.6%) | 19 (29.7%) | 31 (29.5%) | 33 (32%) |
Most common AEs (> 5%), n (%) | ||||
Fatigue | 15 (23.8%) | 17 (26.6%) | 27 (25.7%) | 30 (29.1%) |
Anaemia | 9 (14.3%) | 13 (20.3%) | 15 (14.3%) | 22 (21.4%) |
Headache | 8 (12.7%) | 11 (17.2%) | 10 (9.5%) | 12 (11.7%) |
Nausea | 4 (6.3%) | 4 (6.3%) | 7 (6.7%) | 8 (7.8%) |
Serious AEs, n (%) | 1 (1.6%) | 1 (1.6%) | 2 (1.9%) | 1 (1%) |
Deaths | 1 (1.6%) | 0 (0%) | 2 (1.9%) | 0 (0%) |